Fgf-21 formulations
AssigneeBristol-Myers Squibb Company
InventorsThomas PALM, Mehrnaz KHOSSRAVI, Sanket PATKE
Life of this patent
Estimating the term…
Abstract
The present application provides pharmaceutical formulations comprising a FGF-21 polypeptide, e.g., a modified FGF-21 polypeptide such as PEG-FGF-21, and one or more stabilizers such as the chelator DPTA. The formulations can be can further stabilized by including a surfactant such as polysorbate 80 and/or adjusting the pH to about 7.1. Also provided are methods of manufacture, methods of treatment, and kits.
Claims130
A pharmaceutical formulation comprising a fibroblast growth factor 21 (FGF-21) polypeptide and an aminopolycarboxylic acid cation chelator, wherein the formulation has improved stability compared to a reference formulation that does not contain the aminopolycarboxylic acid cation chelator.
A pharmaceutical formulation comprising:
- (i) a FGF-21 polypeptide;
- (ii) histidine at a concentration between about 10 mM and about 50 mM;
- (iii) sucrose at a concentration between about 100 mM and about 1M;
- (iv) Polysorbate 80 at a concentration between about 0.01% and about 0.1% (w/v);
- and,
- (v) DTPA at a concentration between about 10 μM and about 100 μM;
- wherein the pH of the formulation is between about 6.7 and about 7.5.
A pharmaceutical formulation comprising:
- (i) a FGF-21 polypeptide;
- (ii) histidine at a concentration of about 20 mM;
- (iii) sucrose at a concentration of about 600 mM;
- (iv) Polysorbate 80 at a concentration of about 0.05% (w/v);
- and
- (v) DTPA at a concentration of about 50 μM;
- wherein the pH is about 7.1.
A pharmaceutical formulation comprising:
- (i) a FGF-21 polypeptide;
- (ii) histidine at a concentration of 20 mM;
- (iii) sucrose at a concentration of 600 mM;
- (iv) Polysorbate 80 at a concentration of 0.05% (w/v);
- and
- (v) DTPA at a concentration of 50 μM;
- wherein the pH is 7.1.
A pharmaceutical formulation comprising:
- (i) a FGF-21 polypeptide;
- (ii) histidine at a concentration of about 20 mM;
- and
- (iii) sucrose at a concentration of about 600 mM;
- wherein the pH is about 7.0.
A pharmaceutical formulation comprising:
- (i) a FGF-21 polypeptide;
- (ii) histidine at a concentration of 20 mM;
- and
- (iii) sucrose at a concentration of 600 mM;
- wherein the pH is 7.0.
A pharmaceutical formulation comprising:
- (i) PEG-FGF-21 at a concentration of about 10 mg/mL;
- (ii) histidine at a concentration of about 20 mM;
- (iii) sucrose at a concentration of about 600 mM;
- (iv) Polysorbate 80 at a concentration of about 0.05% (w/v);
- and
- (v) DTPA at a concentration of about 50 μM;
- wherein the pH is about 7.1.
A pharmaceutical formulation comprising:
- (i) PEG-FGF-21 at a concentration of about 20 mg/mL;
- (ii) histidine at a concentration of about 20 mM;
- (iii) sucrose at a concentration of about 600 mM;
- (iv) Polysorbate 80 at a concentration of about 0.05% (w/v);
- and
- (v) DTPA at a concentration of about 50 μM;
- wherein the pH is about 7.1.
A pharmaceutical formulation comprising:
- (i) PEG-FGF-21 at a concentration of 10 mg/mL;
- (ii) histidine at a concentration of 20 mM;
- (iii) sucrose at a concentration of 600 mM;
- (iv) Polysorbate 80 at a concentration of 0.05% (w/v);
- and
- (v) DTPA at a concentration of 50 μM;
- wherein the pH is 7.1.
A pharmaceutical formulation comprising:
- (i) PEG-FGF21 at a concentration of 20 mg/mL;
- (ii) histidine at a concentration of 20 mM;
- (iii) sucrose at a concentration of 600 mM;
- (iv) Polysorbate 80 at a concentration of 0.05% (w/v);
- and
- (v) DTPA at a concentration of 50 μM;
- wherein the pH is 7.1.
A method to improve the stability of a pharmaceutical formulation comprising a FGF-21 polypeptide comprising admixing an aminopolycarboxylic acid cation chelator, wherein the formulation has improved stability compared to a reference formulation that does not contain the aminopolycarboxylic acid cation chelator.
A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
- (i) histidine at a concentration between about 10 mM and about 50 mM;
- (ii) sucrose at a concentration between about 100 mM and about 1M;
- (iii) Polysorbate 80 at a concentration between about 0.01% and about 0.1% (w/v);
- and,
- (iv) DTPA at a concentration between about 10 μM and about 100 μM;
- wherein the pH of the formulation is between about 6.7 and about 7.5.
A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
- (i) histidine at a concentration of about 20 mM;
- (ii) sucrose at a concentration of about 600 mM;
- (iii) Polysorbate 80 at a concentration of about 0.05% (w/v);
- and,
- (iv) DTPA at a concentration of about 50 μM;
- wherein the pH is about 7.1.
A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
- (i) histidine at a concentration of 20 mM;
- (ii) sucrose at a concentration of 600 mM;
- (iii) Polysorbate 80 at a concentration of 0.05% (w/v);
- and,
- (iv) DTPA at a concentration of 50 □M;
- wherein the pH is 7.1.
A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
- (i) histidine at a concentration of about 20 mM;
- and,
- (ii) sucrose at a concentration of about 600 mM;
- wherein the pH is about 7.0.
A method to improve the stability of a formulation comprising a FGF-21 polypeptide comprising admixing
- (i) histidine at a concentration of 20 mM;
- and,
- (ii) sucrose at a concentration of 600 mM;
- wherein the pH is 7.0.
A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 10 mg/mL, comprising admixing
- (i) histidine at a concentration of about 20 mM;
- (ii) sucrose at a concentration of about 600 mM;
- (iii) Polysorbate 80 at a concentration of about 0.05% (w/v);
- and,
- (iv) DTPA at a concentration of about 50 μM;
- wherein the pH is about 7.1.
A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 20 mg/mL, comprising admixing
- (i) histidine at a concentration of about 20 mM;
- (ii) sucrose at a concentration of about 600 mM;
- (iii) Polysorbate 80 at a concentration of about 0.05% (w/v);
- and,
- (iv) DTPA at a concentration of about 50 μM;
- wherein the pH is about 7.1.
A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 10 mg/mL, comprising admixing
- (i) histidine at a concentration of 20 mM;
- (ii) sucrose at a concentration of 600 mM;
- (iii) Polysorbate 80 at a concentration of 0.05% (w/v);
- and,
- (iv) DTPA at a concentration of 50 μM;
- wherein the pH is 7.1.
A method to improve the stability of a formulation comprising PEG-FGF-21 at a concentration of about 20 mg/mL, comprising admixing
- (i) histidine at a concentration of 20 mM;
- (ii) sucrose at a concentration of 600 mM;
- (iii) Polysorbate 80 at a concentration of 0.05% (w/v);
- and,
- (iv) DTPA at a concentration of 50 μM;
- wherein the pH is 7.1.
A pharmaceutical formulation made by the process of admixing
- (i) PEG-FGF-21 in amount to achieve a final concentration of about 10 mg/mL;
- (ii) histidine in amount to achieve a final concentration of about 20 mM;
- (iii) sucrose in amount to achieve a final a concentration of about 600 mM;
- (iv) Polysorbate 80 in amount to achieve a final concentration of about 0.05% (w/v);
- and
- (v) DTPA in amount to achieve a final concentration of about 50 μM;
- and
- and adjust the pH at about 7.1.
A pharmaceutical formulation made by the process of admixing
- (i) PEG-FGF-21 in amount to achieve a final concentration of about 20 mg/mL;
- (ii) histidine in amount to achieve a final concentration of about 20 mM;
- (iii) sucrose in amount to achieve a final a concentration of about 600 mM;
- (iv) Polysorbate 80 in amount to achieve a final concentration of about 0.05% (w/v);
- and
- (v) DTPA in amount to achieve a final concentration of about 50 μM;
- and
- and adjust the pH at about 7.1.
A pharmaceutical formulation made by the process of admixing
- (i) PEG-FGF-21 in amount to achieve a final concentration of 10 mg/mL;
- (ii) histidine in amount to achieve a final concentration of 20 mM;
- (iii) sucrose in amount to achieve a final a concentration of 600 mM;
- (iv) Polysorbate 80 in amount to achieve a final concentration of 0.05% (w/v);
- and
- (v) DTPA in amount to achieve a final concentration of 50 μM;
- and
- and adjust the pH at 7.1.
A pharmaceutical formulation made by the process of admixing
- (i) PEG-FGF-21 in amount to achieve a final concentration of 20 mg/mL;
- (ii) histidine in amount to achieve a final concentration of 20 mM;
- (iii) sucrose in amount to achieve a final a concentration of 600 mM;
- (iv) Polysorbate 80 in amount to achieve a final concentration of 0.05% (w/v);
- and
- (v) DTPA in amount to achieve a final concentration of 50 μM;
- and
- and adjust the pH at 7.1.
Dependencies are inferred from the claim text.